Gold J, Marta M, Meier UC et al.(2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Mult Scler Relat Disord vol. 24, 123-128.
MEIER UC, EMTICS Collaborative Group(2018). European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry
Disanto G, Zecca C, MacLachlan S et al.(2018). Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol vol. 83, (6) 1162-1173.
KOCOVSKA E, Mickunas M, Ramien C et al.(2018). The role of inflammation and hypovitaminosis-D in multiple sclerosis, schizophrenia and autism. Neurology, Psychiatry and Brain Research vol. 29,
Rowell D, Nghiem S, Ramagopalan S et al.(2017). Seasonal temperature is associated with Parkinson's disease prescriptions: an ecological study. Int J Biometeorol vol. 61, (12) 2205-2211.
James E, Dua P, Warnes G et al. (2017). The effect of simvastatin on autophagy in mammalian cells. MULTIPLE SCLEROSIS JOURNAL. vol. 23, 790-790.
MEIER U(2017). Vitamin-D Deficiency as a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia and Autism. Frontiers in Psychiatry vol. 8, 47-47.
Sisay S, Lopez L, Mickunas M et al.(2017). Untreated relapsing remitting multiple sclerosis patients show antibody production against Latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. Journal of Neuroimmunology
Gold J, Marta MC, Meier UC et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-189.
Marta M, MacManus D, Yousry T et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-188.
Manson J, Cole E, De¿Ath HD et al.(2016). Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Critical Care vol. 20, (1)
Meier U-C(2016). The role of inflammation in MS and schizophrenia. Neurology, Psychiatry and Brain Research vol. 22, (1) 17-17.
Klionsky DJ, Abdelmohsen K, Abe A et al.(2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy vol. 12, (1) 1-222.
Kuhle J, Disanto G, Dobson R et al.(2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler vol. 21, (8) 1013-1024.
Biela A, Watkinson M, Meier UC et al.(2015). Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. Biosensors and Bioelectronics vol. 68, 660-667.
Sisay S, Rosello A, Henseleit K et al. (2014). Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing-remitting multiple sclerosis patients. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 46-46.
Ramien C, Pachnio A, Sisay S et al.(2014). Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. Mult Scler vol. 20, (6) 751-753.
Panchal, N., Chikte, S., Wilbourn, B.R. et al.(2013). Flow Cytometric Measurement of Cell Organelle Autophagy. Immunology and Microbiology » "Autophagy - A Double-Edged Sword - Cell Survival or Death?", Editors: Yannick, B, INTECH
Disanto G, Watson CT, Meier UC et al.(2013). Month of birth and thymic output. JAMA Neurol vol. 70, (4) 527-528.
Disanto G, Pakpoor J, Morahan JM et al.(2013). Epstein-Barr virus, latitude and multiple sclerosis. Mult Scler vol. 19, (3) 362-365.
Pakpoor J, Disanto G, Gerber JE et al.(2013). The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler vol. 19, (2) 162-166.
Miao T, Raymond M, Bhullar P et al.(2013). Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf. J Immunol vol. 190, (1) 58-65.
Disanto G, Watson CT, Meier UC et al.(2013). Month of birth and thymic output. JAMA Neurol vol. 4, (70) 527-528.
Pakpoor J, Disanto G, Meier UC et al. (2012). Epstein-Barr virus seroprevalence in multiple sclerosis patients: a systematic review and meta-analysis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 368-369.
Tzartos J, Khan G, Cruz-Sadaba M et al. (2012). Association of innate immune activation with latent Epstein - Barr virus infection in active multiple sclerosis lesions. IMMUNOLOGY. vol. 137, 51-51.
ROSELLO A, WARNES G, MEIER UC(2012). Cell death pathways and autophagy in the central nervous system and its involvement in neurodegeneration, immunity and central nervous system infection: to die or not to die – that is the question. Clinical and Experimental Immunology vol. 168, (1) 52-57.
Dobson R, Meier UC, Schmierer K et al. (2012). DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
Tzartos JS, Khan G, Vossenkamper A et al.(2012). Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology vol. 78, (1) 15-23.
Tzartos J, Khan G, Vossenkamper A et al.(2012). Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology
MEIER U (2012). Can latent Epstein-Barr virus infection in the central nervous system contribute to neuroinflammation?. Neurology, Psychiatry and Brain Research. vol. 2,
Rosello A, Warnes G, Meier UC(2012). Cell death pathways and autophagy in the central nervous system and their involvement in neurodegeneration, immunity and CNS infection: to die or not to die - that is the question. Clin. Exp. Immunol. vol. 168, (1) 52-57.
Meier UC, Giovannoni G, Tzartos J et al.(2012). Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?. Clin. Exp. Immunol vol. 167, (1) 1-6.
Tzartos JS, Khan G, Vossenkamper A et al.(2011). Association of innate immune activation with latent Epstein Barr virus in active MS lesions. Neurology vol. 78, (1) 15-23.
Dobson R, Meier UC, Marta M et al.(2011). Vitamin D deficiency - do we follow our own advice?. CLINICAL MEDICINE vol. 11, (6) 521-523.
Dobson R, Meier UC, Schmierer K et al.(2011). Do siblings have markers of multiple sclerosis risk?. MULTIPLE SCLEROSIS JOURNAL vol. 17, S86-S86.
Tzartos JS, Khan G, Cruz-Sadaba M et al.(2011). Innate immune activation is associated with latent Epstein-Barr virus infection in active MS lesions. MULTIPLE SCLEROSIS JOURNAL vol. 17, S350-S350.
Ramagopalan SV, Meier UC, Conacher M et al.(2011). Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis. Arch Neurol vol. 68, (4) 469-472.
Maghzi A-H, Marta M, Bosca I et al.(2011). Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. Pathophysiology vol. 18, (1) 13-20.
Lassmann H, Niedobitek G, Aloisi F et al.(2011). Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain vol. 134, (9) 2772-2786.
Maghzi AH, Marta M, Bosca I et al.(2011). Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time?. Neuroinflammation, Editors: Minagar, A, Elsevier
Meier UC, Giovannoni G(2011). More to come: humoral immune responses in MS. Journal of Neuroimmunology vol. 240-241, 13-21.
Disanto G, Meier U, Giovannoni G et al.(2011). Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development?. Expert Rev Neurother. vol. 9, (11) 1221-1224.
Maghzi AH, Marta M, Bosca I et al.(2010). Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time?. Elsevier
Ramagopalan SV, Dobson R, Meier UC et al.(2010). Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol vol. 9, (7) 727-739.
Campbell SJ, Meier U, Mardiguian S et al.(2010). Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE. Brain Behav Immun. vol. 5, (24) 738-746.
Tzartos J, Khan G, Vossenkaemper A et al. (2009). The anti-viral cytokine interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection. MULTIPLE SCLEROSIS. vol. 15, S276-S276.
Marta M, Meier UC, Lobell A(2009). Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev vol. 8, (6) 506-509.
Maggiore C, Meier UC, Marta M et al. (2009). B Cells and EBV Infection in People with MS. NEUROLOGY. vol. 72, A37-A37.
Peferoen LA, Lamers F, Lodder LN et al.(2009). Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain vol. 132 (Pt 12), (2) 3318-3328.
Jack CS, Arbour N, Blain M et al.(2007). Th-1 polarization of CD4(+) T cells by toll-like receptor 3-activated human microglia. J NEUROPATH EXP NEUR vol. 66, (9) 848-859.
Meier U-C, Owen RE, Taylor E et al.(2005). Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol vol. 79, (19) 12365-12374.
Lucas M, Gadola S, Meier U et al.(2003). Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol.2251-2257.
Tafuro S, Meier UC, McMichael A et al. (2002). EPITOPE-BETA MICROGLOBULIN POLYNUCLEOTIDE FOR ANTI-CANCER IMMUNOTHERAPY. no. PCT/GB2001/004844,
Xu XN, Purbhoo MA, Chen N et al.(2001). A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity vol. 14, (5) 591-602.
Tafuro S, Meier UC, Dunbar PR et al.(2001). Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta 2m fusion molecules. EUR J IMMUNOL vol. 31, (2) 440-449.
Tafuro S, Meier UC, Dunbar R et al.(2001). Reconstitution of antigen presentation in HLA class I negative cancer cells with peptide-beta2m fusion molecules. Eur. J. Immunol. vol. 31, 440-449.
Price D, Meier UC, Klenerman P et al.(1998). The influence of antigenic variation on CTL responses in HIV. Journal of Molecular Medicine699-708.
Meier U, Klenerman P, Griffin P et al.(1995). Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science vol. 270, (5240) 1360-1362.
Klenerman P, Meier UC, Phillips R et al.(1995). The effects of natural altered peptide ligands on the whole blood cytotoxic T-lymphocyte response to human immunodeficiency virus. Eur. J. Immunol. vol. 7, (25) 1927-1931.
Meier UC, Boetzel J, Kellermann J et al. (1994). The cleavage of the bait region of a2-macroglobulin by human immunodeficiency proteinases and by astacin. 431-433.
Meier UC, Billich A, Mann K et al.(1991). Alpha2-macroglobulin is cleaved by HIV-1 protease in the bait region but not in the C-terminal inter-domain region. Biol. Chem. Hoppe-Seyler.1051-1056.
MEIER U. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders
MEIER U, Ko¿ovská E, Gaughran F et al.. Vitamin-D deficiency as a potential environmental risk factor in multiple sclerosis, schizophrenia and autism. Frontiers in Psychiatry